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Abstract
 
In lymphocytes, the Rel transcription factor is essential in establishing a pattern of gene expres-
sion that promotes cell proliferation, survival, and differentiation. Here we show that mitogen-
 
induced expression of interferon (IFN) regulatory factor 4 (
 
IRF-4
 
), a lymphoid-specific
member of the IFN family of transcription factors, is Rel dependent. Consistent with IRF-4
 
functioning as a repressor of IFN-induced gene expression, the absence of 
 
IRF-4
 
 expression in
 
c-rel
 
2/2
 
 B cells coincided with a greater sensitivity of these cells to the antiproliferative activity
of IFNs. In turn, enforced expression of an 
 
IRF-4
 
 transgene restored IFN modulated 
 
c-rel
 
2/2
 
 B
cell proliferation to that of wild-type cells. This cross-regulation between two different signal-
ing pathways represents a novel mechanism that Rel/nuclear factor 
 
k
 
B can repress the tran-
scription of IFN-regulated genes in a cell type–specific manner.
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Introduction
 
During antigen and mitogen stimulation of lymphocytes,
specific genetic programs are established by the coordinated
activation of various signal transduction pathways, which in
turn, lead to morphologic changes, cell division, differenti-
ation, and the acquisition of immunological function. The
temporal patterns of gene expression that underlie these
processes in lymphocytes collectively span a time frame that
extends from minutes to days, with the induction of imme-
diate early and early response genes coinciding with that
period of mitogenic stimulation required to commit a cell
to a program of activation (1).
One group of transcription factors essential for lympho-
cyte activation and immune function is the Rel/nuclear
factor (NF)
 
1
 
-
 
k
 
B proteins (2), homodimers and hetero-
dimers composed of related subunits that are encoded by a
small multigene family. Rel/NF-
 
k
 
B proteins regulate gene
expression by binding to specific decameric sequences (
 
k
 
B
elements) located within the transcriptional regulatory re-
gions of cellular genes, particularly those encoding proteins
involved in immune, acute phase, and inflammatory re-
sponses (3, 4). The five mammalian Rel/NF-
 
k
 
B subunits
share a conserved NH
 
2
 
-terminal domain (Rel homology
domain [RHD]) that encompass sequences essential for
DNA binding, dimerization, and nuclear localization (3).
The 50- and 52-kD forms of NF-
 
k
 
B1 and NF-
 
k
 
B2, re-
spectively, comprise the RHD and lack intrinsic transcrip-
tional transactivating properties, whereas Rel, RelA, and
RelB all possess transactivation domains within their diver-
gent COOH termini (3). In most cell types, the majority of
Rel/NF-
 
k
 
B is sequestered as an inactive cytoplasmic com-
plex with inhibitor or I
 
k
 
B proteins (5, 6). Diverse stimuli
promote the nuclear translocation of cytoplasmic Rel/NF-
 
k
 
B by activating an I
 
k
 
B kinase complex (for a review, see
reference 2) that phosphorylates conserved serine residues
on the I
 
k
 
B proteins, targeting them for ubiquitin-depen-
dent proteosome-mediated degradation (5, 6).
Rel is dispensable for normal embryonic development
and hemopoiesis, but is essential for the division, survival,
differentiation, and immune function of mature lympho-
cytes and macrophages (7–11). To date, most of the genes
known to be direct transcriptional targets of Rel encode
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cytokines, cytokine receptors, and immune-regulatory
molecules such as IL-2, IL-3, GM-CSF, IL-6, TNF-
 
a
 
, IL-
2R
 
a
 
, and inducible nitric oxide synthase (iNOS [2, 3]).
However, impaired expression of these proteins only partly
explains the immune defects exhibited by 
 
c-rel
 
2/2
 
 mice. For
example, the B cell proliferative defect resulting from the
absence of Rel is due to a cell cycle block and enhanced
apoptosis (10). This impaired mitogenic response is a result
of the combined failure to induce the expression of prosur-
vival genes such as 
 
A1
 
 (11), and Rel-regulated genes neces-
sary for G1 progression, the latter of which remain to be
identified.
As part of a strategy aimed at identifying genes regulated
by Rel, the expression of genes normally induced early in
lymphocyte activation were examined in 
 
c-rel
 
2/2
 
 B and T
cells. Among those surveyed, IFN regulatory factor 4 (
 
IRF-4
 
),
a lymphoid-restricted member of the IFN family of tran-
scription factors, emerged as a promising candidate. 
 
IRF-4
 
expression is rapidly induced in resting lymphocytes by mi-
togens (12) with kinetics that closely follow the nuclear in-
duction of Rel (13). Like Rel, it also appears to be critical
in lymphocyte proliferation, as 
 
IRF-4
 
2/2
 
 B and T cells re-
spond poorly to mitogens (14) and deregulated overexpres-
sion of IRF-4 due to the translocation of the gene into the
Ig CH locus occurs in a subset of human multiple myelo-
mas (15). Proteins comprising the IRF family, of which
there are at least 10 members, function either as transcrip-
tional activators or repressors (16). All share a conserved
NH
 
2
 
-terminal domain required for the recognition and
binding of a specific DNA consensus sequence, the IFN
stimulation response element (ISRE) found in the promot-
ers of IFN-regulated genes (17, 18). Although originally
identified as mediating the diverse biological activities of
type I and type II IFNs (19, 20), subsequent studies have
revealed roles for IRFs that are independent of IFN signal-
ing. These include controlling susceptibility to oncogenic
transformation, promoting cell cycle progression, and the
induction of growth arrest and programmed cell death (18).
Here we show that IRF-4, a repressor of ISRE-mediated
transcription, while normally rapidly upregulated in mito-
gen stimulated B and T cells is not induced in activated
 
c-rel
 
2/2
 
 lymphocytes. This impaired expression of IRF-4,
which coincides with a hyperresponsiveness of 
 
c-rel
 
2/2 
 
lym-
phocytes to type I and type II IFNs and enhanced expres-
sion of certain IFN-induced genes, establishes a novel
mechanism that Rel/NF-
 
k
 
B can regulate IFN-induced
gene expression in a cell type–specific fashion.
 
Materials and Methods
 
Mice.
 
The generation of the 
 
c-rel
 
2/2
 
 (7) and 
 
nfkbl1
 
2/2
 
 (21)
mice has been described previously. All mutant mouse strains
have been backcrossed for greater than nine generations with
C57BL/6 mice.
 
Genomic Clones, Plasmid Constructs, and Retroviral Expression
Vector.
 
Phage genomic clones encompassing the murine 
 
IRF-4
 
gene (12) were a gift of Prof. Tak Mak (Ontario Cancer Insti-
tute, Toronto, Canada). Plasmids IRF4 Pst1–chloramphenicol
 
acetyltransferase (CAT), IRF4 H3-CAT, and IRF4 Sph1-CAT
consisted of the 2644-bp Pst1–Avr1, 1195-bp Hind3–Avr1, and
498-bp Sph1–Avr1 genomic fragments, respectively, from the
murine 
 
IRF-4
 
 5
 
9
 
 flanking sequence inserted upstream of 
 
CAT
 
 in
the promoterless reporter plasmid pBCAT3 (22). IRF4 
 
k
 
B1
 
m
 
-
CAT and IRF4 
 
k
 
B2
 
m
 
-CAT are derivatives of IRF4 Pst1-CAT,
in which NF-
 
k
 
B binding sites 
 
k
 
B1 (5
 
9
 
-GGGGATCCAC-3
 
9
 
 at
 
2
 
1733 to 
 
2
 
1724) and 
 
k
 
B2 (5
 
9
 
-GGGATCCCCC-3
 
9
 
 at 
 
2
 
686 to
 
2
 
657) were altered by in vitro mutagenesis (23) to 5
 
9
 
-GGT-
CATAAAC-3
 
9
 
 and 5
 
9
 
-GTCATCAACC-3
 
9
 
, respectively, or in
the case of IRF4 
 
k
 
B1
 
m
 
/
 
k
 
B2
 
m
 
-CAT, where both sites have been
mutated. The reporter plasmid pA3luc-ISRE comprising four
copies of the ISRE consensus sequence 5
 
9
 
-GTACCAGTTTCG-
GTTTCCCTTG-3
 
9
 
 inserted upstream of the minimal mouse
H2D
 
k
 
 promoter in the reporter plasmid pGem-luc (Promega)
was provided by H. Thomas (Walter and Eliza Hall Institute for
Medical Research). The expression plasmid pCMDIRF-4 was
generated by inserting a 2-kb Xba1–Hind3 murine 
 
IRF-4
 
 cDNA
encompassing the entire IRF-4 coding region into pCMD-8. A
cDNA encompassing the murine IRF-4 coding region fused in
frame with an NH
 
2
 
-terminal FLAG tag was cloned as a BglII–
EcoR1 insert into the retroviral expression vector pMSCV-
IRES–green fluorescent protein (GFP) (a gift of Dr. L. Van Par-
ijs, California Institute of Technology, Pasadena, CA).
 
Purification of Primary B and T Lymphocytes.
 
Small resting B
and T lymphocytes were purified from the spleens of 6–8-wk-old
wild-type, 
 
nfkb1
 
2/2
 
, and 
 
c-rel
 
2/2
 
 mice by negative sorting (10)
on a FACS
 
® 
 
or FACStar
 
PLUS™
 
 cell sorter (Becton Dickinson).
The purity of all sorted B and T lymphocytes was verified by
staining a portion of the cells with PE-labeled anti-B220 or anti-
Thy1 antibodies, respectively (Caltag Labs) and ranged between
95 and 99%.
 
Cell Culture and Lymphocyte Activation in Tissue Culture.
 
The
Jurkat T cell line was maintained in RPMI 1640 supplemented
with 8% FCS, and 293T fibroblasts were grown in DMEM/8%
FCS. The B cell lines 404.1 and B1.1 have been described previ-
ously (11) and were cultured in DMEM/10% FCS/50 
 
m
 
M BME.
Primary B and T lymphocytes were cultured in the high glucose
version of DMEM supplemented with 13 mM folic acid, 250
mM 
 
l
 
-asparagine, 50 
 
m
 
M 2-ME, and 10% FCS. Spleen cells
were cultured at an initial concentration of 10
 
6
 
 cells/ml, and
FACS
 
®
 
-purified B or T lymphocytes were cultured at an input
concentration of 3 
 
3
 
 10
 
5
 
 cells/ml. All primary B or T cells were
stimulated in vitro with LPS (Difco), affinity-purified goat anti–
mouse IgM (Fab
 
9
 
) fragment (Jackson ImmunoResearch Labora-
tories), rat anti–mouse radioprotective (RP) mAbs (24), Con A
(Amersham Pharmacia Biotech), PMA and ionomycin (Sigma
Chemical Co.), or plate-coated mouse anti-CD3 and anti-CD28
mAbs as described previously (11). In proliferation assays for
which the effect of IFNs were assessed, either recombinant IFN-
 
a
 
or IFN-
 
g
 
 (gifts of Drs.
 
 
 
P.
 
 
 
Hertzog, Monash University, Mel-
bourne, Australia, and T. Kay, The Walter and Eliza Hall Insti-
tute of Medical Research, Melbourne, Australia) were added at
increasing 10-fold concentrations (1–10
 
3
 
 U/ml) with the mito-
gen combinations anti-RP/LPS or Con A/IL-2 (for B and T
cells, respectively) for 72 h. Cellular proliferation was measured
by adding 0.5 
 
m
 
Ci of [
 
3
 
H]thymidine for 6 h. Afterwards, cells
were harvested onto glass fiber filters, and incorporated radioac-
tivity was quantitated by scintillation counting.
 
Transfections, CAT Assays, and Luciferase Assays.
 
Jurkat T cells
and 293T fibroblasts were transiently transfected using Super-
fect (QIAGEN) as described previously (11). Equimolar amounts
(1–2 
 
m
 
g) of IRF4-CAT plasmids or the pluc-ISRE reporter plas- 
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mid (1 
 
m
 
g) were transfected alone or with a threefold molar excess
of pDAMP56, PDAMP56c-rel (25), pCTax (26), pCDMI
 
k
 
B-
 
a
 
m
 
(27), pCDMIRF-1 (19), pCDMIRF-2 (20), or pCDMIRF-4.
After 48 h, Jurkat and 293T cells were harvested and CAT or lu-
ciferase assays were performed on cell extracts that had been stan-
dardized for protein content. Transfections were performed five
times, with a maximum variance of 
 
z
 
15% observed between
replicate experiments.
 
Retroviral Production and Infection.
 
Retroviral stocks were ob-
tained by Superfect (QIAGEN)-mediated transfection of the
pMSCV-IRES-GFP and pMSCV-IRES-GFP:IRF-4 vectors
into BOS23 cells as described (28). B cell lines 404.1 and B1.1
were infected by incubating each of 10
 
6
 
 cells for 2 h with 0.25 ml
(
 
z
 
10
 
6
 
 virus/ml) of viral stock in 1 ml of media containing 5 
 
m
 
g/
ml of polybrene. Cells were washed once, resuspended in 3 ml of
complete medium, and incubated for 48 h. Infected cells were
identified as GFP
 
1
 
 and then cloned in 96-well plates using the
cell deposition unit of the FACStar
 
PLUS™
 
.
 
Immunoblotting. Total cell extracts from z106 cells boiled in
0.5% SDS were electrophoresed on 10% SDS-polyacrylamide gels
and transferred to nitrocellulose membranes as described (13). Fil-
ters were incubated with affinity-purified mouse anti-FLAG M2
specific monoclonal Ig (Sigma Chemical Co.) for detection of
FLAG-tagged IRF-4. Bound antibody was then revealed by horse-
radish peroxidase–conjugated goat anti–mouse Ig (Silenus) using
enhanced chemiluminescence (Amersham Pharmacia Biotech).
Northern Blot Analysis. Northern blot hybridization on total
RNA isolated from cells using RNAgents (Promega) was per-
formed essentially as described (11). Filters were washed in 0.23
SSC, 0.1% SDS at 658C and exposed to autoradiography at
2708C. For successive hybridizations, filters were boiled in 10
mM EDTA, 0.1% SDS to remove the bound probe before the
rehybridization. The probes were 2-kb Xbal–Hind3 murine
IRF-4 cDNA (29), and 1.1-kb Pst1 rat glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) cDNA (30) inserts radiolabeled
with [a-32P]dATP by primer extension.
Semiquantitative Reverse Transcription PCR. Total RNA was
isolated from mouse primary splenic B cells (106) and embryonic
fibroblasts (3 3 105) that were nonactivated or stimulated for 8 h
with 103 IU/ml of recombinant IFN-a in the absence or pres-
ence of 50 mg/ml of LPS using RNAgents (Promega). cDNA
synthesis on equivalent amounts of total RNA was performed es-
sentially as described (9). For semiquantitative PCR, cDNA was
added to a cocktail comprising 50 mM KCl, 2 mM MgCl2, 10
mM Tris-HCl, pH 8.3, 0.01% (wt/vol) gelatin, 0.5 mM dNTPs,
1 U of Taq polymerase (Ampli Taq: Perkin-Elmer Cetus) and 1
mM of each oligonucleotide in a final volume of 50 ml. After an
initial 5-min denaturation at 948C, the cDNA was amplified for
25 cycles with each cycle programmed for denaturation at 948C
for 45 s, annealing at 588C for 60 s, followed by elongation at
728C for 90 s. Samples were then fractionated on a 1% agarose
gel. The sequence of the oligonucleotides used for the amplifica-
tion of murine 29–59 oligoadenylate synthetase (OAS) and b-actin
mRNA were: 29-59OAS, 59 oligo CGCTGGACAAGTTCAT-
AGAGGATT (nucleotides 70–93, according to the sequence
of Ichii et al. [31]), 39 oligo TTTCCTTGATGAACTCTC-
CCCGTC (nucleotides 319–342, according to the sequence
of Ichii et al. [31]); and b-actin, 59 oligo CTGAAGTACCCAT-
TGAACATGGC (nucleotides 278–303, according to the se-
quence of Tokunaga et al. [32]), 39 oligo CAGAGCAGTA-
ATCTCCTTCTGCAT (nucleotides 1016–1040 [32]); the
29-59OAS and b-actin PCR products are 272 and 762 nucle-
otides in length, respectively.
Electrophoretic Mobility Shift Assays. IRF4 kB1 and IRF4 kB2
probes were prepared by end-labeling the double stranded oligo-
nucleotides 59-TCACTTCTGGGGGATCCACACAACGAG-39
and 59-TGAGTACTCAGGGATCCCCCATCTCTT-39, re-
spectively, and electrophoretic mobility shift assays reactions were
performed with 1–2 mg of nuclear extract as described (13). For
competition analysis, a 50-fold excess of unlabeled IRF4 kB1,
IRF4 kB2, IRF4 kB1m (59-TCACTTCTGGGTCATAAACA-
CAACGAG-39), or IRF4 kB2m (59-TGAGTACTCAGTCAT-
CAACCATCTCTT-39) competitor DNA was added to the re-
action at room temperature 15 min before the addition of
radiolabled probe. For supershift analysis, antibodies that specifi-
cally recognize NF-kB1, RelA, Rel (13), or NF-kB2 (sc 298;
Santa Cruz Biotechnology) were incubated on ice for 30 min be-
fore the addition of radiolabeled probe. All electrophoretic mo-
bility shift assay reactions were incubated for 20 min at room
temperature, 2 ml of Ficoll dye was added, and the reactions were
fractionated on 5% nondenaturing polyacrylamide gels. Gels were
then dried and exposed to autoradiography at 2708C.
Results
Rel Induction of Murine IRF-4 Transcription Is Mediated by
kB Elements in the Promoter. In an attempt to identify
novel Rel-regulated genes, RNA hybridization studies
were performed on c-rel2/2 lymphocytes to examine the ex-
pression of genes normally induced during mitogen stimu-
lation with kinetics that parallel Rel translocation into the
nucleus. One gene, IRF-4 (also referred to as Pip [29], IC-
SAT [IFN consensus binding protein in activated T cells;
33], or LSIRF [lymphoid IFN stimulatory response factor;
12]), encodes a lymphoid-specific member of the IFN fam-
ily of transcription factors that is strongly upregulated by
various mitogens in normal and nfkb12/2 B and T cells
within 2 h, but is barely induced in stimulated c-rel2/2 lym-
phocytes (Fig. 1).
To determine if Rel directly regulates IRF-4 transcrip-
tion, a nested set of murine IRF-4 promoter truncations
Figure 1. Mitogen-induced
expression of IRF-4 mRNA is
markedly reduced in c-rel2/2
lymphocytes. 10-mg samples of
total RNA isolated from un-
treated or mitogen-stimulated
wild-type,  nfkb12/2, or c-rel2/2
splenocytes activated in culture
for 2 h were analyzed by North-
ern blot hybridization. Filters
were sequentially hybridized
with murine IRF-4 and rat
GAPDH cDNA probes and ex-
posed to autoradiography for
24–48 h. Untreated cells (lane 1)
and mitogen-activated cells
(lanes 2–7). The stimuli were
Con A (lane 2); anti-CD3 plus
anti-CD28 antibodies (lane 3);
phorbol ester (lane 4); LPS (lane
5); anti-RP antibodies (lane 6);
and anti-IgM antibodies (lane 7).1284 Rel Induction of IRF-4 Modulates IFN Responsiveness
extending upstream of the 59 untranslated region (1177),
inserted 59 of CAT in a promoterless reporter plasmid (Fig.
2 A; 22) were transiently transfected into Jurkat T cells
with or without a c-rel expression vector. Basal activity of
the full-length promoter, IRF4 Pst1-CAT (22465 to
1177) was equivalent to that of the truncated clones, IRF4
H3-CAT (21010 to 1177) and IRF4 Sph1-CAT (2320
to 1177) (Fig. 2 B, lanes 3, 5, and 7), indicating that the
sequences necessary for basal transcription appear to reside
within 320 nucleotides upstream of the transcription start
site. In contrast, whereas IRF4 Pst1-CAT was induced 3.5-
fold by Rel, the Rel-dependent expression of IRF4 H3-
CAT and IRF4 Sph1-CAT was significantly reduced or
completely ablated (Fig. 2 B, compare lanes 4, 6, and 8).
These findings indicated that at least two sequences residing
between 22465 and 2320 were mediating Rel-dependent
transcription. As this region of the murine IRF-4 promoter
encompassed two putative Rel/NF-kB binding sites at
21733 (kB1: 59-GGGGATCCAC-39) and 2686 (kB2:
59-GGGATCCCC-39) (12), the requirement of these ele-
ments for Rel-mediated transcription was tested directly by
mutating either or both of these sequences. Promoter con-
structs, IRF4 kB1m-CAT, IRF4 kB2m-CAT, and IRF4
kB1m/kB2m-CAT, that contain either or both mutant kB
sites within the context of the full-length promoter re-
tained normal basal promoter activity (Fig. 2 B, lanes 3, 9,
11, and 13). However, mutations in kB1 (lane 10) or kB2
(lane 12) diminished the Rel-dependent induction of IRF4
Pst1-CAT by twofold, while the disruption of both sites
(lane 14) eliminated Rel-induced transcription. These re-
sults demonstrate that these two kB elements are both nec-
essary and sufficient for Rel-dependent IRF-4 transcrip-
tion.
Mitogen-induced Nuclear Rel Complexes Bind to Both kB El-
ements in the IRF-4 Promoter. The ability of the two IRF-4
kB sites to bind nuclear Rel complexes was examined by
electrophoretic mobility shift assays (Fig. 3). Single major
complexes expressed in quiescent wild-type and c-rel2/2 T
cells (Fig. 3 A, lanes 1 and 3) bound kB1 (denoted C2) and
kB2 (denoted C4) probes. Within 2 h of anti-CD3/anti-
CD28 stimulation, novel complexes (C1 and C3 for kB1
and kB2 probes) were detected in wild-type (Fig. 3 A, lane
2) but not c-rel2/2 T cells (lane 4). The binding specificity
of all complexes was demonstrated in normal (Fig. 3 A,
lanes 5, 6, 9, and 10) and c-rel2/2 (lanes 7, 8, 11, and 12) T
cells by competition with excess unlabeled IRF-4 kB1,
IRF-4  kB2 (lanes 9–12), or the corresponding mutant
probes (lanes 5–8). Equivalent results were obtained for
Figure 2. Functional analysis of the murine IRF-4 promoter. (A) Schematic repre-
sentation of the IRF-4 59 flanking region and the CAT reporter plasmids. The numbers
in parenthesis indicate the position of restriction enzyme sites in the murine IRF-4 59
flanking sequence according to the sequence of Matsuyama et al. (reference 12). The
filled boxes represent the two putative NF-kB binding sites kB1 (59-GGGGATC-
CAC-39: 21733 to 21724) and kB2 (59-GGGATCCCCC-39: 2686 to 2677), whereas the corresponding symbol with a cross represents the mutated
motifs kB1m (59-GGTCATAAAC-39) and kB2m (59-GTCATCAACC-39). The arrow denotes the transcription initiation site and the CAT gene is de-
picted as an open box. Plasmid nomenclature is indicated to the right of each construct. (B) Both IRF-4 NF-kB motifs contribute to Rel-dependent
transcription in T cells. Jurkat cells were transiently transfected with 2 mg of the reporter plasmids pCAT (lanes 1 and 2), IRF4 Pst1-CAT (lanes 3 and
4), IRF4 H3-CAT (lanes 5 and 6), IRF4 Sph1-CAT (lanes 7 and 8), IRF4 kB1m-CAT (lanes 9 and 10), IRF4 kB2m-CAT (lanes 11 and 12), or IRF4
kB1m/kB2m-CAT (lanes 13 and 14) plus 10 mg of the expression plasmid DAMP56 containing no insert (lanes 1, 3, 5, 7, 9, 11, and 13) or c-rel (lanes
2, 4, 6, 8, 10, 12, and 14). Chloramphenicol acetylation for transfections with pDAMP56 or pDAMP56c-rel is indicated by white and black bars, re-
spectively. Results represent the mean percentage of chloramphenicol acetylation 6 SD obtained from six separate sets of transient transfections.1285 Grumont et al.
normal and c-rel2/2 B cells activated with anti-IgM anti-
bodies (results not shown).
The composition of complexes binding IRF-4 kB1 and
kB2 in normal resting and mitogen-stimulated T lympho-
cytes was examined by supershift analysis using antibodies
specific for the different Rel/NF-kB subunits (Fig. 3 B).
Mitogen-induced complexes C1 and C3 were super-
shifted with antibodies specific for NF-kB1 (lane 6) and
Rel (lane 7), but not RelA (lane 8), demonstrating that
both complexes predominantly comprise NF-kB1/Rel
heterodimers. Although C2 and C4 have similar mobilities
to NF-kB1 homodimers, neither complex was supershifted
Figure 3. Rel/NF-kB complexes in resting and mitogen-stimulated T cells. Nuclear extracts (1–2 mg) isolated from purified normal, c-rel2/2, and
nfkb12/2 splenic T cells stimulated with anti-CD3 plus anti-CD28 antibodies for 2 h, then incubated with 32P-radiolabeled IRF4 kB1 or IRF4 kB2
probes were resolved on 5% nondenaturing polyacrylamine gels and exposed to autoradiography for 8–24 h at 2708C. (A) Nuclear complexes rapidly
induced by mitogen that bind IRF4 kB1 and IRF4 kB2 are absent in c-rel2/2 T cells. Nuclear extracts from resting (lanes 1, 3, 5, 7, 9, and 11) and anti-
CD3/anti-CD28–stimulated (lanes 2, 4, 6, 8, 10, and 12) normal (lanes 1, 2, 5, 6, 9, and 10) and c-rel2/2 (lanes 3, 4, 7, 8, 11, and 12) T cells were prein-
cubated in the absence (lanes 1–4) or presence of a 50-fold molar excess of unlabeled mutant (kB1m, kB2m: lanes 5–8) or wild-type (kB1, kB2: lanes
9–12) probe before adding radiolabeled IRF4 kB1 or IRF4 kB2. The inducible slow mobility complexes binding to kB1 and kB2 are designated C1 and
C3, respectively, while the constitutive fast mobility complexes binding kB1 and kB2 are designated C2 and C4, respectively. (B) Inducible complexes
C1 and C3 are Rel/NF-kB1 heterodimers. Nuclear extracts from resting (lanes 1–4) and anti-CD3/anti–CD28 stimulated (lanes 5–8) wild-type splenic
T cells were incubated with preimmune (lanes 1 and 5) or NF-kB1 (lanes 2 and 6), Rel (lanes 3 and 7) or RelA (lanes 4 and 8)–specific sera before adding
radiolabeled IRF4 kB1 or IRF4 kB2 probes. (C) Mitogen-induced kB binding complexes in nfkbl2/2 T cells. Nuclear extracts from resting (lanes 1, 3,
and 5) and anti-CD3/anti–CD28 stimulated (lanes 2, 4, and 6) nfkbl2/2 T cells were preincubated in the absence (lanes 1 and 2) or presence of a 50-fold
molar excess of unlabeled mutant (kB1m, kB2m: lanes 3 and 4) or wild-type (kB1 or kB2: lanes 5 and 6) binding sites before adding radiolabeled IRF4
kB1 or IRF4 kB2 probes. The inducible slow mobility complexes binding to kB1 and kB2 are designated C5 and C7, respectively, while the constitu-
tive fast mobility complexes binding kB1 and kB2 are designated C6 and C8, respectively. (D) Inducible kB binding complexes C5 and C7 in nfkbl2/2 T
cells are Rel homodimers. Nuclear extracts from anti-CD3/anti-CD28–stimulated nfkbl2/2 T cells were incubated with preimmune (lane 1) or NF-kB1
(lane 2), NF-kB2 (lane 3), Rel (lane 4), or RelA (lane 5)–specific sera before adding radiobalelled IRF4 kB1 or IRF4 kB2 probes.1286 Rel Induction of IRF-4 Modulates IFN Responsiveness
with various NF-kB1–specific antibodies or antibodies di-
rected to other Rel/NF-kB proteins. The identity of pro-
tein(s) in C2 and C4 remains to be determined.
Although mitogen-induced IRF-4 expression coincided
with the binding of NF-kB1/Rel to IRF-4 kB1 and kB2,
the normal induction of IRF-4 mRNA in mitogen-stimu-
lated nfkb12/2 lymphocytes prompted us to examine the
basis of NF-kB1–independent IRF-4 transcription. DNA
binding assays performed with nuclear extracts from resting
or anti-CD3/anti-CD28 antibody–stimulated nfkb12/2 T
lymphocytes are shown in Fig. 3 C. IRF-4 kB1 and kB2
bound complexes in resting cells (lane 1, denoted C6 and
C8) and novel complexes of slower mobility (lane 2, de-
noted C5 and C7) induced in mitogen activated cells. Su-
pershift studies (Fig. 3 D) indicated that the induced com-
plexes C5 and C7 appear to be Rel homodimers, whereas
C6 and C8 were not recognized by Rel/NF-kB–specific
antisera (lanes 2, 3, 4, and 5). While the roles of C6 and C8
in IRF-4 transcription are unknown, ablation of C6 bind-
ing by competition with unlabeled IRF-4 kB1 mutant
probe (Fig. 3 C, lane 4) indicates that this protein(s) does
not bind the IRF-4 kB1 probe via the consensus kB site.
Collectively, these data establish that mitogen induced
IRF-4 expression coincides with the binding of Rel com-
plexes to both kB elements in the IRF-4 promoter.
Rel-deficient B Cells Exhibit Increased Responsiveness to Type
I and Type II IFNs. IFN-induced gene expression is con-
trolled by the coordinated interplay of transcriptional ac-
tivators and repressors (18). IFN-regulated transactiva-
tors IRF-1 and ISGF3 induce transcription by binding to
ISREs found in the promoters and enhancers of IFN-regu-
lated genes (18), while a negative regulator such as IRF-2 is
thought to repress transcription by competitive binding to
these motifs (17). Since IRF-4 functions as a repressor of
IFN-induced gene expression (33, 34), one consequence of
the inability to upregulate IRF-4 expression during the mi-
togenic activation of c-rel2/2 lymphocytes may be increased
responsiveness of these cells to the action of IFNs. Inhibi-
tion of normal lymphocyte proliferation by high concen-
trations of type I and type II IFNs (35, 36) prompted us to
compare the proliferative response of normal and c-rel2/2 B
cells over a wide range of IFN-a and IFN-g concentrations
(Fig. 4). The stimulus anti-RP plus LPS was chosen for
these experiments because in contrast to individual mito-
gens which fail to induce c-rel2/2 B cell proliferation (7),
certain mitogen or mitogen plus cytokine combinations
function synergistically to promote the proliferation of
Rel-deficient cells (7, 10). Inhibition of B cell proliferation
over a wide range of IFN-a and IFN-g concentrations
(Figs. 4, A and B) was significantly greater in c-rel2/2 cul-
tures. This heightened sensitivity of c-rel2/2 B cells to the
antiproliferative activity of both cytokines was concentra-
tion-dependent. While inhibition of c-rel2/2 B cell prolifer-
ation was more pronounced with increasing concentrations
of IFN-g (Fig. 4 C), the difference in the inhibition of nor-
mal and c-rel2/2 B cells by IFN-a was maximal at 102 IU/
ml (Fig. 4 B). Consistent with the specificity of IRF-4 in-
duction by Rel in lymphocytes and its proposed role in
modulating IFN responsiveness, proliferating c-rel2/2 T
cells but not c-rel2/2 fibroblasts display a heightened sensi-
tivity to the antiproliferative activity of IFNs (Grumont,
R., unpublished results).
Enforced IRF-4 Expression in c-rel2/2 B Cells Restores Nor-
mal IFN Responsiveness. We have previously shown that
surface IgM1 c-rel2/2 B cell lines, like primary c-rel2/2 B
cells undergo apoptosis upon B cell receptor engagment
due in part to an absence of Rel-induced A1 expression
(11). To ascertain if these cell lines could also be useful
models in determining whether the Rel-dependent induc-
tion of IRF-4 in B cells has a direct role in modulating the
responsiveness of proliferating B cells to IFNs, we first ex-
amined the expression of IRF-4 in control and c-rel2/2 B
cell lines. In contrast to the constitutive expression of IRF-4
in the control B cell line W404.1, IRF-4 mRNA was
not detected in the c-rel2/2 B cell line B1.1 (Fig. 5 A). To
determine if an absence of IRF-4 expression in B1.1 was
associated with an increased sensitivity to the antiprolifera-
tive action of IFNs, both W404.1 and B1.1 were treated
with a range of IFN-a and IFN-g concentrations for 72 h
and proliferation assessed by tritiated thymidine incorpora-
tion (Fig. 5 B). Consistent with the trends observed for
primary B cells, after 72 h, proliferation of the c-rel2/2 B
cell line B1.1 was significantly less over a range of IFN-a
and IFN-g concentrations compared with that of W404.1.
The role of IRF-4 in reducing the antiproliferative action
of IFNs was examined by infecting the W404.1 and B1.1
cell lines with a retrovirus expressing NH4-terminally Flag-
tagged IRF-4. Clones of each cell line expressing compara-
ble levels of exogeneous IRF-4 (Fig. 5 C) were then
treated with IFN-a or IFN-g for 72 h and proliferation as-
sessed (Fig. 5 D). These experiments, which showed that
enforced expression of IRF-4 restores c-rel2/2 B cell prolif-
eration, established that IRF-4 can modulate IFN-induced
inhibition of lymphocyte proliferation to that of c-rel1/1 B
cells in the presence of IFN.
Figure 4. c-rel2/2 B cells dis-
play greater sensitivity to the an-
tiproliferative activity of type I
and type II IFNs. Resting splenic
lymphocytes from normal (filled
circles) and c-rel2/2 (open circles)
mice were stimulated for 72 h
with optimal concentrations of
anti-RP antibodies plus LPS in
the absence or presence of 1, 10,
100, or 1,000 U/ml of IFN-a or
IFN-g. Cellular proliferation
was measured at 24-h intervals
over 72 h by [3H]thymidine in-
corporation. Proliferation of
normal and c-rel2/2 B cells in
the presence of a particular con-
centration of IFN at the 72-h
time point is represented in this
figure as a percentage of
[3H]thymidine incorporated by
normal or c-rel2/2 cells, respectively, in the absence of IFN. All results
represent the mean 6 SD from five experiments.1287 Grumont et al.
Rel Induction of IRF-4 Coincides with a Repression of IFN-
regulated Gene Expression. The heightened responsiveness
of c-rel2/2 lymphocytes to the action of IFN led us to de-
termine if Rel could be shown to modulate ISRE-depen-
dent transcription. This was determined by comparing
ISRE-dependent transcription in Jurkat T cells or 293T
embryonic kidney epithelial cells transiently transfected
with an ISRE-regulated reporter plasmid and various com-
binations of expression vectors encoding IRF-1, IRF-2,
IRF-4, and Rel (Fig. 6 A). IRF-1–induced ISRE-depen-
dent transcription was reduced significantly in both cell
types by cotransfection with an equimolar concentration of
IRF-2 or IRF-4 plasmids (compare lanes 2 and 7 with
lanes 3, 4, 8, and 9). However, Rel was only able to re-
press IRF-1–induced gene expression (sixfold, lane 5) in
Jurkat T cells. Consistent with Rel repressing IRF-1–
dependent transcription in a lymphoid-specific manner,
Northern blot analysis of transiently transfected Jurkat and
293T cells (Fig. 6 B) revealed that IRF-4 mRNA levels
were only upregulated in Jurkat T cells transfected with
c-rel (lane 4). Collectively, these findings are consistent with
Rel repressing ISRE-dependent transcription in a lym-
phoid-restricted manner by upregulating IRF-4.
IFN-regulated endogeneous gene expression was also
examined in c-rel2/2 cells. We focused on the gene encod-
ing the 1.7-kb transcript for 29-59OAS because the molec-
ular basis of its IFN- or IRF-1–induced transcription has
been well studied (30, 36–38) and transcription of the hu-
man gene is repressed by IRF-4 (33). The IFN induction
of 29-59OAS mRNA was examined in normal and c-rel2/2
fibroblasts and B cells stimulated with IFN-a or IFN-a
Figure 5. Constitutive IRF-4 expression promotes c-rel2/2 B cell proliferation in the presence of IFNs. (A) IRF-4 is not expressed in c-rel2/2 B cell
lines. 5 mg samples of total RNA isolated from the immortalized B cell lines W404.1 (c-rel1/1; lane 1) and B1.1 (c-rel2/2; lane 2) were analyzed by North-
ern blot hybridization. Filters were sequentially hybridized with murine IRF-4 and rat GAPDH cDNA probes and exposed for autoradiography for 24 h.
The results obtained with these two cell lines were representative of other independent c-rel1/1 and c-rel2/2 cell lines. (B) c-rel2/2 B cell lines are more sen-
sitive to the antiproliferative activity of IFNs. The W404.1 (c-rel1/1; open symbols) and B1.1 (c-rel2/2; filled symbols) B cell lines were either untreated or
stimulated for 72 h with 1, 10, 100, or 1,000 U/ml of IFN-a (circles) or IFN-g (squares). Cellular proliferation was measured at 24-h intervals over 72 h
by [3H]thymidine incorporation. Proliferation of all cell lines in the presence of a particular concentration of IFN at the 72-h time point is represented in
this figure as a percentage of [3H]thymidine incorporated by normal or c-rel2/2 cells, respectively, in the absence of IFN. All results represent the mean 6
SD from four experiments. (C) Expression of exogeneous IRF-4. Whole cell extracts from W404.1 (c-rel1/1; lanes 1 and 2) and B1.1 (c-rel2/2; lanes 3 and
4) cells that had been infected with a control retrovirus (lanes 1 and 3) or a retrovirus expressing NH2-terminally FLAG-tagged IRF-4 (lanes 2 and 4)
were resolved by SDS-PAGE and subjected to Western blot analysis using mAbs directed to the FLAG epitope. (D) Enforced IRF-4 expression over-
comes the heightened anti-proliferative action of IFNs that result from the loss of Rel. The cell lines W404.1 (circles) and B1.1 (triangles) that were in-
fected with a control retrovirus (open symbols) or a virus expressing FLAG-tagged IRF-4 (filled symbols) were either untreated or stimulated for 72 h
with 1, 10, 100, or 1,000 U/ml of IFN-a or IFN-g. The data shown represents the 72-h time point and are expressed as a percentage of [3H]thymidine
incorporated by normal or c-rel2/2 cells, respectively, in the absence of IFN. All results represent the mean 6 SD from four experiments.
Figure 6. Rel regulation of IRF-1–
dependent transcription. (A) Rel repres-
sion of IRF-1–dependent transcription is
lymphoid specific. Jurkat T cells (lanes 1–5)
and 293T fibroblasts (lanes 6–10) were
transiently transfected with 2 mg of the
ISRE-regulated reporter plasmid pluc-
ISRE in the absence (lanes 1 and 6) or
presence of an equimolar concentration of
expression vectors encoding IRF-1 (lanes
2 and 7) IRF-1 plus IRF-2 (lanes 3 and
8), IRF-1 plus IRF-4 (lanes 4 and 9), or
IRF-1 plus c-rel (lanes 5 and 10). Lu-
ciferase activity for transfections with vec-
tor control (white bars), IRF-1 (black
bars), IRF-1 plus IRF-2 (hatched bars),
IRF-1 plus IRF-4 (stippled bars), or IRF-1
plus c-rel (cross-hatched bars) represent
the mean activity 6 SD obtained from
four separate sets of transient transfections.
(B) Rel repression of IRF-1–regulated
transcription in T cells coincides with
IRF-4 induction. 10-mg samples of total
RNA isolated from Jurkat and 293T cells
transiently transfected with 15 mg of
pDAMP56 (vector control) or pDAMP56
c-rel after 48 h were analyzed by Northern
blot hybridization with murine IRF-4 and
rat GAPDH cDNA probes. Filters were
exposed to autoradiography for 24 h.1288 Rel Induction of IRF-4 Modulates IFN Responsiveness
plus LPS. A representative example of these experiments is
shown in Fig. 7. Consistent with previous findings for var-
ious cell types (37), 29-59OAS expression is absent or low
in unstimulated normal and mutant fibroblasts or lympho-
cytes (lanes 1, 2, 7, and 8). While the induction of 29-
59OAS mRNA by IFN-a or LPS plus IFN-a is equivalent
in wild-type and c-rel2/2 fibroblasts (lanes 3-6), mRNA
levels are between four- and fivefold higher than normal in
c-rel2/2 B cells activated with IFN-a and LPS (lanes 11 and
12). This is in contrast to stimulation with IFN-a only,
where 29-59OAS mRNA levels are equivalent in wild-
type and mutant B cells (lanes 9 and 10). Since IRF-4 is
upregulated by mitogens but not IFNs (12), reduced ex-
pression of 29-59OAS in normal but not c-rel2/2 B cells
treated with LPS and IFN-a is consistent with repression
of 29-59OAS transcription arising from the Rel-dependent
induction of IRF-4.
Induction of IRF-4 by Tax Is Rel/NF-kB Dependent.
Since IRF gene expression is often induced in cells in re-
sponse to viral infection (20, 38), it was noteworthy that
IRF-4 is expressed constitutively in HTLV-1–induced T
cell leukemias, but not in other T cell tumors of varying
etiology (33). Consistent with this finding, Tax, a potent
HTLV-1–encoded transcriptional activator essential for vi-
ral mediated oncogenesis upregulates IRF-4 expression in
Jurkat cells (33). As Tax induces the expression of various
cellular genes by activating or enhancing the activity of cel-
lular transcription factors including Rel/NF-kB proteins
(39, 40), we examined whether Tax-induced IRF-4 tran-
scription was mediated by Rel/NF-kB (Fig. 8). While Tax
upregulated the IRF4 Pst1-CAT reporter plasmid fourfold
in Jurkat cells (compare lanes 4 and 5), an IkB-a super re-
pressor reduced the Tax-dependent induction of the IRF-4
promoter to near basal levels (lane 6). Cotransfections of
tax and the IRF-4 kB promoter mutants established that
both IRF-4 kB1 and kB2 are essential for Tax-dependent
IRF-4 transcription. Whereas Tax-mediated transactivation
of IRF4 kB1m-CAT (lane 8) and IRF4 kB2m-CAT (lane
11) was 70 and 50%, respectively, of wild-type promoter
activity, the loss of both kB sites completely abolished
transactivation (lane 14). As was the case with IRF4 Pst1-
CAT, the diminished Tax-induced activation of IRF-4 re-
porter plasmids containing kB1 or kB2 mutations was fur-
ther reduced to basal levels by IkB-am (lanes 9 and 12).
These findings establish that the Tax induction of IRF-4
transcription in T cells is mediated by Rel/NF-kB.
Discussion
Previous studies have shown that in lymphocytes, Rel is
crucial in promoting cellular activation and the acquisition
of immunological function (2). Consistent with the immu-
nological component of Rel function, cytokine genes such
as IL-2, IL-3, and GM-CSF are transcriptional targets of
Rel (7, 8). Here we show that expression of IRF-4, a lym-
phoid-specific IFN regulatory factor is directly induced by
Rel in activated lymphocytes and that an absence of Rel
coincides with a heightened responsiveness of lymphocytes
to type I and type II IFNs. The implications of this finding
for lymphocyte proliferation, viral replication, and the
cross-regulation of IFN signaling by Rel/NF-kB are dis-
cussed.
Rel-dependent Transcription. Here we show mitogen-
induced  IRF-4 transcription is Rel-dependent and is regu-
lated by two kB elements located in the IRF-4 promoter that
Figure 7. Rel modulates 29-59OAS expression in lymphocytes. Total
mRNA isolated from wild-type (lanes 1, 3, 5, 7, 9, and 11) or c-rel2/2
(lanes 2, 4, 6, 8, 10, and 12) mouse embryonic fibroblasts (lanes 1–6) and
B cells (lanes 7–12) that were non-activated (lanes 1, 2, 7, and 8) or stim-
ulated with IFN-a (lanes 3, 4, 9, and 10) or LPS plus IFN-a (lanes 5, 6,
11, and 12) for 8 h was subjected to semiquantitative reverse transcription
PCR using 29-59OAS– and b-actin–specific primers. PCR products were
fractionated on a 1% agarose gel.
Figure 8. Tax-induced IRF-4 transcription is Rel/NF-kB-dependent.
Jurkat cells were transiently transfected with 2 mg of the reporter plas-
mids pCAT (lanes 1–3), IRF4 Pst1-CAT (lanes 4–6), IRF4 kB1m-CAT
(lanes 7–9), IRF4 kB2m-CAT (lanes 10–12) or IRF4 kB1m/kB2m-CAT
(lanes 13–15) in the absence (lanes 1, 4, 7, 10, and 13) or presence of a
threefold molar excess of an expression plasmid for HTLV-1 Tax (lanes
2, 5, 8, 11, and 14) or expression plasmids for Tax plus IkB-am (lanes 3,
6, 9, 12, and 15). Chloramphenicol acetylation for transfections with
pCDM-8 (vector control), pCTax or pCDM IkB-am are indicated by
white, black, and hatched bars, respectively. Results represent the mean
percentage of chloramphenicol acetylation 6 SD obtained from five sep-
arate sets of transient transfections.1289 Grumont et al.
bind Rel/NF-kB complexes. Although the major nuclear
complex induced in lymphocytes that binds to both IRF-4
kB elements is NF-kB1/Rel, normal upregulation of IRF-4
in nfkb12/2 lymphocytes that results from Rel homodimers
binding to these sites indicates that NF-kB1 is a nonessential
heterodimeric partner of Rel in controlling the transcription
of this gene. A similar finding has been made for mitogen-
induced regulation of A1 expression, which is also under the
transcriptional control of Rel/NF-kB (11). Together, this es-
tablishes that under normal physiological conditions, Rel ho-
modimers can function as transcriptional activators.
Rel/NF-kB binding sites 59-GGGG/ARRNNA/CC-39
comprise a conserved 59 half site, GGGA/GR, and a diver-
gent 39 half site. Both dimer partners contribute to DNA
binding, with different subunits binding to the half sites
with varying affinity (41, 42). Since NF-kB1 preferentially
interacts with the conserved 59 half site (41), NF-kB1 ho-
modimers bind with strongest affinity to symmetrical mo-
tifs (41). By contrast, DNA sequences randomly selected in
vitro to bind recombinant Rel homodimers with high af-
finity (59-NGGRNA/TTTCC-39) exhibit considerable se-
quence variation (43). The IRF-4 and A1 kB sites, all of
which bind NF-kB1 homodimers, Rel homodimers, and
NF-kB1/Rel heterodimers, comprise the consensus se-
quence 59-G/AGGGATCCA/C
A/C-39. As each of these sites
shares the invariant core motif 59-GGGATCC-39, we sug-
gest that this may represent a signature sequence for func-
tional Rel/NF-kB sites that bind Rel homodimers. Inter-
estingly, the A1 and IRF4 kB sites do not conform to the
artificial high-affinity Rel consensus sequences, but instead
are more closely related to NF-kB1 homodimer binding
sites (43). While the reason for this difference is unclear,
one plausible explanation may be that physiological kB
sites need to bind Rel homodimers with lower affinity than
the artificial sites which were selected in vitro to favor
high-affinity protein–DNA interactions.
IRF-4, a Transcriptional Target of Rel: Implications for the
Immune Response and Cell Division. Our findings establish
that Rel/NF-kB transcription factors are dichotomous reg-
ulators of IFN signaling. While NF-kB has been shown to
be important in viral-induced human IFN-b transcription
(44), we show here that Rel can modulate IFN-regulated
gene expression in lymphocytes by inducing IRF-4, a re-
pressor of ISRE-regulated transcription. While higher than
normal 2959OAS expression in mitogen plus IFN-activated
c-rel2/2 lymphocytes is consistent with a role for IRF-4 in
the transcriptional repression of this gene, the expression of
certain other IFN-induced genes is not altered in c-rel2/2 B
and T cells (Grumont, R., unpublished results). The reason
for the selective modulation of IFN-regulated gene expres-
sion in c-rel2/2 lymphocytes remains to be determined. For
example, it may reflect the mechanism(s) by which IRF-4
blocks IFN-induced transcription, which is thought to oc-
cur either by direct competition with activators for binding
to ISREs (33, 34) or through protein–protein interactions
with activators such as IRF-1 or ISGF3, as has been pro-
posed for IFN consensus sequence binding protein (ICSBP)-
mediated repression (45).
In contrast to other IRF genes, the expression of IRF-4
is not regulated by type I or type II IFNs, but instead is in-
duced by Rel/NF-kB in response to mitogenic stimula-
tion. As IRF-4 is required for lymphocyte proliferation
(14) and inhibits IFN-induced transcription (33), it had
been proposed that this novel mode of IRF regulation rep-
resents a mechanism that permits lymphocyte activation
under conditions normally refractory to cellular prolifera-
tions (29, 34). Particularly as the growth inhibitory activity
of IFNs (35) would be detrimental to lymphocyte function
during an immune response, attenuating the effects of IFN
by upregulating IRF-4 could be envisaged as a means of
maximizing the antiviral immune response of B and T cells
in a microenvironment with high local concentrations of
these cytokines. Certainly, such a dual role for IRF-4 in
regulating lymphocyte proliferation and IFN gene expres-
sion is compatible with the finding that IRF-4 is a cellular
gene induced by HTLV-1 Tax. As retroviral replication is
dependent on the division of target cells (46), Tax induc-
tion of IRF-4 would contribute in maintaining an activated
cellular state, while aiding HTLV-1–infected cells to evade
the anti-viral response by repressing IFN-regulated gene
expression.
Although IFR-4 is a transcriptional target of Rel that
regulates lymphocyte responsiveness to IFNs during cellu-
lar activation, the finding that mature B and T cells from
young IRF-42/2 mice, like c-rel2/2 lymphocytes, proliferate
poorly when treated with diverse mitogens (14) indicates
that IRF-4 is also important in controlling IFN-indepen-
dent lymphocyte proliferation. Although these observations
support a model in which c-rel2/2 B cell proliferative de-
fects are in part due to an inability to upregulate IRF-4, this
appears to be at odds with the finding that lymphoprolifer-
ative disorders develop in older IRF-42/2 mice (14), but
not c-rel2/2 animals (7). The apparent paradox that an ab-
sence of IRF-4 can both reduce and increase lymphocyte
proliferation supports an emerging idea that normal cellular
proliferation requires the balanced expression of IRF tran-
scriptional activators and repressors, and that altering this
balance perturbs cell growth (18). Such a model would also
account for the observation that dysregulated overexpres-
sion of IRF-4, resulting from a translocation of the gene
into the Ig CH locus contributes to the development of
multiple myeloma in humans (15). The finding that IRF-4
is a transcriptional target of Rel may also have important
implications for v-Rel–mediated transformation. Because
v-Rel lacks part of the Rel transactivation domain, the
transcriptional activity of the viral oncoprotein differs from
that of Rel (47, 48). Consequently, a v-Rel–induced
change in the normal pattern of IRF-4 expression could
perturb cell growth and may help to explain the basis of
lymphoid-specific transformation by v-Rel.
Although it remains to be determined which IRF-4–
regulated genes are involved in the control of lymphocyte
proliferation, 2959OAS represents an interesting candidate.
2959OAS functions to convert ATP into 29-59-oligoadeny-
late, which in turn activates the latent endonuclease RNase
L (49). In addition to the 2959OAS/RNase L pathway be-1290 Rel Induction of IRF-4 Modulates IFN Responsiveness
ing a key mechanism for inhibiting viral replication (50),
activation of this enzyme is also likely to be important in
degrading cellular RNA and as a consequence modulating
normal cellular functions. Since overexpression of 2959OAS
can inhibit cellular proliferation (51), the enhanced expres-
sion of 2959OAS in mitogen-activated c-rel2/2 lymphocytes
treated with IFN-a may account in part for the increased
sensitivity of these cells to the antiproliferative action of this
cytokine. Ultimately, the identification of direct targets of
Rel and genes further along the transcriptional cascade will
offer important insights into understanding how Rel regu-
lates cellular processes in response to a variety of extracellu-
lar signals.
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